BioSpace News Archive

Mevion Medical Systems announced the sales of two HYPERSCAN® Pencil Beam Scanning upgrades to American Shared Hospital Services.

20% vapor tax will dissuade smokers from quitting

Sunwarrior now provides a collagen-building protein peptides supplement that is completely plant-based.

Agilent Technologies Inc. (NYSE: A) announced today the shipping of a new instrument that offers laboratories a more affordable, low-throughput option for analyzing the quality of RNA and DNA samples.

Nxt-ID, Inc. (NASDAQ: NXTD), a provider of healthcare devices as well as payment, credential management, and authentication platform services, announces the filing of its financial results for the year ended December 31, 2018.

Basel, April 02, 2019 – Novartis, a global leader in immuno-dermatology and rheumatology announced today that the China Health AuthorityNMPA approved Cosentyx® (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to severe plaque psoriasis in adultpatients who are candidates for systemic therapy or phototherapy.

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has completed the acquisition of the US rights to Proleukin® (aldesleukin, human recombinant interleukin-2), following US anti-trust clearance.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.

Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, will announce its Preliminary Results for the full year ending 31 December 2018 on 10 April 2019.

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (“Sierra”), the licence holder advancing clinical cancer candidate SRA737, announced late yesterday that new preclinical data for SRA737, its Chk1 inhibitor, plus low dose gemcitabine (LDG), in combination with anti-PD-L1 immunotherapy, has been reported in a late-breaking oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019,